High-risk endometrial carcinoma in early stages: Hospital Italiano de Buenos Aires, oncological results
Introduction: Endometrial cancer is the second most frequent gynecological tumor in Argentina, representing 6% of all cancers in women. The objective of this study is to evaluate the oncological and perioperative results in patients with high-risk endometrial cancer (HREC) limited to the uterus, tre...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2023
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/40821 |
| Aporte de: |
| id |
I10-R327-article-40821 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
endometrial neoplasms survival endometrium neoplasias de endometrio sobrevida endometrio neoplasias do endométrio sobrevida endométrio |
| spellingShingle |
endometrial neoplasms survival endometrium neoplasias de endometrio sobrevida endometrio neoplasias do endométrio sobrevida endométrio Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz High-risk endometrial carcinoma in early stages: Hospital Italiano de Buenos Aires, oncological results |
| topic_facet |
endometrial neoplasms survival endometrium neoplasias de endometrio sobrevida endometrio neoplasias do endométrio sobrevida endométrio |
| author |
Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz |
| author_facet |
Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz |
| author_sort |
Odetto, Diego |
| title |
High-risk endometrial carcinoma in early stages: Hospital Italiano de Buenos Aires, oncological results |
| title_short |
High-risk endometrial carcinoma in early stages: Hospital Italiano de Buenos Aires, oncological results |
| title_full |
High-risk endometrial carcinoma in early stages: Hospital Italiano de Buenos Aires, oncological results |
| title_fullStr |
High-risk endometrial carcinoma in early stages: Hospital Italiano de Buenos Aires, oncological results |
| title_full_unstemmed |
High-risk endometrial carcinoma in early stages: Hospital Italiano de Buenos Aires, oncological results |
| title_sort |
high-risk endometrial carcinoma in early stages: hospital italiano de buenos aires, oncological results |
| description |
Introduction: Endometrial cancer is the second most frequent gynecological tumor in Argentina, representing 6% of all cancers in women. The objective of this study is to evaluate the oncological and perioperative results in patients with high-risk endometrial cancer (HREC) limited to the uterus, treated at the Hospital Italiano de Buenos Aires, between January 2010-2018.
Methods: Retrospective cohort study that evaluated perioperative results, disease-free survival at 2, 4 years in patients with HREC.
Results: Of a total of 123 patients, 74 met the inclusion criteria. Serous tumors were the most frequent histological type, n=38 (51%), while dedifferentiated tumors were the least frequent, n=2 (3%). Of all the patients included, 56 (76%) received at least one adjuvant treatment. Taxol platinum-based chemotherapy was implemented in 28 patients (38%), while 24 (33%) received a combination of chemotherapy and radiotherapy. The median follow-up time was 2.9 years. Disease-free survival in patients with stage IA at 2 and 4 years was 71% (95% CI 55-82) and 63% (CI 46-76), respectively, while those with stage IB were 53 (95% CI 33-70) and 38 (95% CI 19-58). Regarding the surgical approach, no significant differences were found in disease-free or overall survival when comparing the laparoscopic with the laparotomy approach (p=0.06).
Conclusion: Only the FIGO stage showed an increased probability of death or relapse regardless of the type of adjuvant treatment and the type of surgery approach. Perioperative complications were similar in both approaches. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2023 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/40821 |
| work_keys_str_mv |
AT odettodiego highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT pugamariaceleste highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT reyvalzacchiguidomartin highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT saadijosemartin highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT zamoralilianabeatriz highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT riggimariacecilia highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT perrottamyriambeatriz highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT odettodiego highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT pugamariaceleste highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT reyvalzacchiguidomartin highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT saadijosemartin highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT zamoralilianabeatriz highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT riggimariacecilia highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT perrottamyriambeatriz highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT odettodiego highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT pugamariaceleste highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT reyvalzacchiguidomartin highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT saadijosemartin highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT zamoralilianabeatriz highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT riggimariacecilia highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT perrottamyriambeatriz highriskendometrialcarcinomainearlystageshospitalitalianodebuenosairesoncologicalresults AT odettodiego carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT pugamariaceleste carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT reyvalzacchiguidomartin carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT saadijosemartin carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT zamoralilianabeatriz carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT riggimariacecilia carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT perrottamyriambeatriz carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT odettodiego carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT pugamariaceleste carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT reyvalzacchiguidomartin carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT saadijosemartin carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT zamoralilianabeatriz carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT riggimariacecilia carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT perrottamyriambeatriz carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT odettodiego carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT pugamariaceleste carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT reyvalzacchiguidomartin carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT saadijosemartin carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT zamoralilianabeatriz carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT riggimariacecilia carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT perrottamyriambeatriz carcinomadeendometriodealtoriesgoenestadiosinicialesresultadosoncologicoshospitalitalianodebuenosaires AT odettodiego carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT pugamariaceleste carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT reyvalzacchiguidomartin carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT saadijosemartin carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT zamoralilianabeatriz carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT riggimariacecilia carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT perrottamyriambeatriz carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT odettodiego carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT pugamariaceleste carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT reyvalzacchiguidomartin carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT saadijosemartin carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT zamoralilianabeatriz carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT riggimariacecilia carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT perrottamyriambeatriz carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT odettodiego carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT pugamariaceleste carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT reyvalzacchiguidomartin carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT saadijosemartin carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT zamoralilianabeatriz carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT riggimariacecilia carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos AT perrottamyriambeatriz carcinomaendometrialdealtoriscoemestagioinicialhospitalitalianodebuenosairesresultadosoncologicos |
| first_indexed |
2024-09-03T21:04:29Z |
| last_indexed |
2025-02-05T22:05:28Z |
| _version_ |
1823256743057031168 |
| spelling |
I10-R327-article-408212024-11-05T13:36:36Z High-risk endometrial carcinoma in early stages: Hospital Italiano de Buenos Aires, oncological results Carcinoma de endometrio de alto riesgo en estadios iniciales: resultados oncológicos, Hospital Italiano de Buenos Aires Carcinoma endometrial de alto risco em estágio inicial: Hospital Italiano de Buenos Aires, resultados oncológicos Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz Odetto, Diego Puga, Maria Celeste Rey Valzacchi, Guido Martin Saadi, Jose Martin Zamora, Liliana Beatriz Riggi, Maria Cecilia Perrotta, Myriam Beatriz endometrial neoplasms survival endometrium neoplasias de endometrio sobrevida endometrio neoplasias do endométrio sobrevida endométrio Introduction: Endometrial cancer is the second most frequent gynecological tumor in Argentina, representing 6% of all cancers in women. The objective of this study is to evaluate the oncological and perioperative results in patients with high-risk endometrial cancer (HREC) limited to the uterus, treated at the Hospital Italiano de Buenos Aires, between January 2010-2018. Methods: Retrospective cohort study that evaluated perioperative results, disease-free survival at 2, 4 years in patients with HREC. Results: Of a total of 123 patients, 74 met the inclusion criteria. Serous tumors were the most frequent histological type, n=38 (51%), while dedifferentiated tumors were the least frequent, n=2 (3%). Of all the patients included, 56 (76%) received at least one adjuvant treatment. Taxol platinum-based chemotherapy was implemented in 28 patients (38%), while 24 (33%) received a combination of chemotherapy and radiotherapy. The median follow-up time was 2.9 years. Disease-free survival in patients with stage IA at 2 and 4 years was 71% (95% CI 55-82) and 63% (CI 46-76), respectively, while those with stage IB were 53 (95% CI 33-70) and 38 (95% CI 19-58). Regarding the surgical approach, no significant differences were found in disease-free or overall survival when comparing the laparoscopic with the laparotomy approach (p=0.06). Conclusion: Only the FIGO stage showed an increased probability of death or relapse regardless of the type of adjuvant treatment and the type of surgery approach. Perioperative complications were similar in both approaches. Introducción: En Argentina el cáncer de endometrio es el segundo tumor ginecológico más frecuente, representando el 6% de todos los cánceres en mujeres. El objetivo de este trabajo es evaluar los resultados oncológicos y perioperatorios, en pacientes con cáncer de endometrio de alto riesgo (CEAR) limitados al útero tratadas en el Hospital Italiano de Buenos Aires entre enero 2010-2018. Métodos: Estudio de cohorte retrospectivo que evaluó los resultados perioperatorios, la supervivencia libre de enfermedad a los 2, 4 años en pacientes con CEAR. Resultados: 74 pacientes cumplieron con los criterios de inclusión. Los tumores serosos fueron los más frecuente n=38 (51%), mientras que los desdiferenciados, los de menor frecuencia, n=2 (3%). 56 (76%) pacientes recibieron al menos un tratamiento adyuvante. El tratamiento sistémico fue implementado en 28 pacientes (38%), mientras que 24 (33%) recibieron una combinación de quimioterapia y radioterapia. La mediana de seguimiento fue de 2,9 años. La supervivencia libre de enfermedad, en pacientes con estadio IA a los 2 y 4 años fue de 71% (IC 95% 55-82) y 63 % (IC 46 -76) respectivamente, mientras que aquellas que presentaban un estadio IB fue de 53 (IC 95% 33-70) y 38 (IC 95% 19-58). En cuanto a la vía quirúrgica de abordaje, no se encontraron diferencias significativas en la supervivencia libre de enfermedad ni en las complicaciones perioperatorias. Conclusión: Sólo el estadio FIGO mostró un aumento en la probabilidad de muerte o recaída independientemente del tipo de tratamiento adyuvante realizado y de la vía de abordaje seleccionada. Introdução: Na Argentina, o câncer de endométrio (CE) é o segundo tumor ginecológico mais frequente, representando 6% de todos os cânceres em mulheres. O objetivo deste trabalho é avaliar os resultados oncológicos e perioperatórios em pacientes com câncer de endométrio de alto risco (CHER) limitado ao útero, atendidas no Hospital Italiano de Buenos Aires, entre janeiro de 2010-2018. Métodos: Estudo de coorte retrospectivo que avaliou resultados perioperatórios, sobrevida livre de doença em 2, 4 anos em pacientes com HREC. Resultados: 74 preencheram os critérios de inclusão. Os tumores serosos foram mais frequente, n=38 (51%), enquanto os tumores indiferenciados foram os menos frequentes, n=2 (3%). De todos os pacientes incluídos, 56 (76%) receberam pelo menos um tratamento adjuvante. A quimioterapia foi implementada em 28 pacientes (38%), enquanto 24 (33%) receberam uma combinação de quimioterapia e radioterapia. O tempo médio de seguimento foi de 2,9 anos. A sobrevida livre de doença em pacientes com estágio IA em 2 e 4 anos foi de 71% (IC 95% 55-82) e 63% (IC 46-76), respectivamente, enquanto aqueles com estágio IB foram de 53 (IC 95% 33- 70) e 38 (95% CI 19-58). Em relação à abordagem cirúrgica, não foram encontradas diferenças significativas na sobrevida livre de doença ou global ao comparar a abordagem laparoscópica com a laparotomia (p=0,06). Conclusão: Apenas o estágio FIGO apresentou maior probabilidade de óbito ou recidiva independente do tipo de tratamento adjuvante e do tipo de abordagem cirúrgica. As complicações perioperatórias foram semelhantes em ambas as abordagens. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2023-12-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion text texto texto text/html application/pdf text/xml https://revistas.unc.edu.ar/index.php/med/article/view/40821 10.31053/1853.0605.v80.n4.40821 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 80 No. 4 (2023): Publicaciones especiales por 80° Aniversario; 352-366 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 80 Núm. 4 (2023): Publicaciones especiales por 80° Aniversario; 352-366 Revista da Faculdade de Ciências Médicas de Córdoba; v. 80 n. 4 (2023): Publicaciones especiales por 80° Aniversario; 352-366 1853-0605 0014-6722 10.31053/1853.0605.v80.n4 spa https://revistas.unc.edu.ar/index.php/med/article/view/40821/44353 https://revistas.unc.edu.ar/index.php/med/article/view/40821/44119 https://revistas.unc.edu.ar/index.php/med/article/view/40821/47063 Derechos de autor 2023 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |